As it turned out the Federal Antimonopoly service, 197 items of cheap domestic cost up to 50 rubles medicines from the list vital is already discontinued in the near future manufacturers will refuse to issue 160 more products from this segment.
At the disposal of “Kommersant” got the letter sent to the government in November 2015, in which the Agency proposes to raise one-time adjustable cheap prices (up to 50 rubles) medicine from the list vital 5$.
Vital and essential drugs (VED) — this is a list of medicines whose prices are regulated by the government so as to ensure their availability to the population. In the list for 2016 — 646 international nonproprietary names (INN). This corresponds to about 23.5 thousand trading dosage forms, explained in an interview with TV Veronika Skvortsova. According to DSM Group, the sales of drugs from the list of essential drugs on the retail commercial market in Russia amounted in 2015 244,6 billion rubles, which is about a third of the market.
“The main reason for cessation of production is low profitability or unprofitability of production because of increased costs for raw materials”, — quotes the edition of lines from the document.
In March 2015, the government submitted a draft resolution by which the prices of cheap medicines included in the list of vital and essential drugs (VED), it was proposed to raise by 30%. However, it was not accepted because of the “unreasonably large increase”.
In February 2016, health Minister Veronika Skvortsova said that Russia has reduced the range and import of vital medicines in the segment of up to 50 rubles, She explained that to import cheap drugs becomes unprofitable due to the devaluation of the ruble, their range had decreased by 8-9%.
The market is vitally important medicines in Russia
244,6 billion rubles the volume of the retail market of ED in monetary terms, in 2015 — by 4.5% more than in 2014
1.6 billion packages amounted to the retail market EDL in real terms in 2015 is 1.3% less than in 2014
34.3% of totaled sales in rubles of essential drugs on the retail commercial market in 2015
6.3 per cent was the share of sales in the segment of vital and essential drugs up to 50 rubles in 2015
At 8.8% of increased prices for essential drugs in 2015
Novartis, Sanofi and Abbott have been the largest importers of essential drugs in Russia in the first nine months of 2015. Collectively they imported essential drugs amounting to 45.5 billion rubles.
Three times — up to RUR 32 — rose validol for 2014-2015 compared with 2013
On 487% to 33,5 million rbl., has increased sales of antiviral drug Tamiflu in Moscow in January 2016, compared with January of 2015
1,25 trln rbl. the volume of the pharmaceutical market in Russia — 8.5% more than in 2014
Source: DSM Group, Ministry of health, RNC Pharma, Rosstat
According to the newspaper, in the near future its proposals to support domestic producers of medicines shall publish the Ministry of industry and trade. A source in the social block of the government told the publication that the Agency has proposed to issue subsidies to those Russian companies, which produce unprofitable drugs from the essential drugs list.